Value of urinary NMP-22 in patients with renal cell carcinoma

Urology

Volumn 60, Issue 4, 2002, Pages 593-597

  Ozer, Gokhan ^a   Altinel, Mert ^a   Kocak, Burak ^a   Yazicioglu, Ahmet ^a   Gonenc, Faruk ^a  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX PROTEIN; NUCLEAR MATRIX PROTEIN 22; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; HOSPITAL DEPARTMENT; HUMAN; KIDNEY CARCINOMA; MALE; NEPHRECTOMY; OUTCOMES RESEARCH; PARTIAL NEPHRECTOMY; PATIENT MONITORING; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TRANSITIONAL CELL CARCINOMA;

CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0036775820     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01857-5     Document Type: Article

References (31)

1. Greenlee R.T., Murray T., Bolden S., et al. Cancer statistics 2000. Ca Cancer J Clin. 50:2000;7-33.
2. Devesa S.S., Silverman D.T., McLaughlin J.K., et al. Comparison of the descriptive epidemiology of urinary tract cancers. Cancer Causes Control. 1:1990;133-141.
3. Nelson W.G., Pienta K.J., Barrack K.J., et al. The role of the nuclear matrix in the organization and function of DNA. Annu Rev Biophys Chem. 15:1986;457-475.
4. Berezney R., Coffey D.S. Identification of a nuclear protein matrix. Biochem Biophys Res Commun. 60:1974;1410-1417.
5. Berezney R., Coffey D.S. Nuclear matrix isolation and characterization of a framework structure from rat liver nuclei . J Cell Biol. 73:1977;616-637.
6. Coming D.E., Okada I.A. Nuclear proteins. III. The fibrillar nature of the nuclear matrix. Exp Cell Res. 103:1976;341-360.
7. Fisher P.A., Berrios M., Blobel G. Isolation and characterization of a proteinaceous subnuclear fraction composed of nuclear matrix, peripheral lamina, and nuclear pore complexes from embryos of Drosophila melanogaster. J Cell Biol. 92:1982;674-686.
8. 3 cells. J Cell Biol. 72:1977;192-208.
9. Wunderlich F., Herlan G. A reversible contractile nuclear matrix; its isolation, structure and composition. J Cell Biol. 73:1977;271-278.
10. Capco D.G., Wan K.M., Penman S. The nuclear matrix three-dimensional architecture and protein composition . Cell. 29:1982;847-858.
11. Bouvier D., Hubert J., Seve A., et al. Three-dimensional approaches to the residual structure of histone-depleted HeLa cell nuclei. J Ultrastruct Res. 87:1984;112-123.
12. Pienta K.J., Partin A.W., Coffey D.S. Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res. 49:1989;2525-2532.
13. Zippe C., Pandrangi L., Agarwal A. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol. 161:1999;62-65.
14. Miyanaga N., Akaza H., Tsukamoto T., et al. Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria. Int J Urol. 6:1999;173-177.
15. Yang C.H., Lambie E.J., Synder M. NuMa an unusually long and coiled coil related protein in the mammalian nucleus . J Cell Biol. 116:1992;1303-1317.
16. Soloway M.S., Briggman V., Carpintino G.A., et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol. 156:1996;363-367.
17. Wiener H.G., Mian C., Haitel A., et al. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol. 159:1998;1876-1880.
18. Hughes J., Katz R.L., Rodriguez-Villanueva J., et al. Urinary matrix protein 22 (NMP22) a diagnostic adjunct to urine cytologic examination for detection of recurrent transitional cell carcinoma of the bladder . Diagn Cytopathol. 20:1999;285-290.
19. Konety B.R., Nangia A.K., Nguyen T.T., et al. Identification of nuclear matrix protein alterations associated with renal cell carcinoma. J Urol. 159:1998;1359-1363.
20. Huang S., Rhee E., Patel H., et al. Urinary NMP22 and renal cell carcinoma. Urology. 55:2000;227-230.
21. Fuhrman S.A., Lasky L.C., Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 6:1982;655-660.
22. Beahrs O.H., for the American Joint Committee on Cancer Manual for Staging of Cancer . 1992;201 JB Lippincott, Philadelphia.
23. Khanuja P.S., Lehr J.E., Soule H.D., et al. Nuclear matrix proteins in normal and breast cancer cells. Cancer Res. 53:1993;3394-3398.
24. Keesee S.K., Meneghini M.D., Szaro S.P., et al. Nuclear matrix proteins in human colon cancer. Proc Natl Acad Sci USA. 91:1994;1913-1916.
25. Partin A.W., Getzenberg R.H., Carmichael M.J., et al. Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res. 53:1993;744-746.
26. Getzenberg R.H., Konety B.R., Oeler T.A., et al. Bladder cancer associated nuclear matrix proteins. Cancer Res. 56:1996;1690-1694.
27. Donat T.L., Sakr W., Lehr J.E., et al. Unique nuclear matrix protein alterations in head and neck squamous cell carcinomas intermediate biomarker candidates . Otolaryngol Head Neck Surg. 114:1996;387-393.
28. Bander N.H., Finstad C.L., Cordon-Cardo C., et al. Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets renal cell carcinomas. Cancer Res. 49:1989;6774-6780.
29. Oosterwijik E., Ruiter D.J., Hoedemaeker P.H.J., et al. Monoclonal antibody G250 recognizes a determinant present in renal cell carcinomas and absent from normal kidney. Int J Cancer. 38:1986;489-501.
30. Pantuck A.J., Zisman A., Belldegrun A.S. The changing natural history of renal cell carcinoma. J Urol. 166:2001;1611-1623.
31. Sharma S., Zippe C.D., Pandrangi L., et al. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol. 162:1999;53-57.